Answers are grounded in this paper and cite their sources.
The key pathology of Alzheimer's disease (AD) is the progressive accumulation of misfolded amyloid beta proteins (A) in extracellular and intracellular spaces. It is an age related, complicated disorders involving multifactor, including neuro-inflammation, oxidative damage along with A deposition. These events may work either independently, or together lead to neuronal degeneration, thus perturb neuronal communications, which ultimately show a long term cognitive and motor dysfunction. The therapy for this disease is still unclear and under active investigation. Although several synthesized compounds, small molecules, drugs have been investigated to prevent further neurodegeneration, some of them have demonstrated partial inhibition of aggregation of the A and their neurotoxicity, but unfortunately, most of them show unsatisfactory outcome. However, recently, as a potent anti-amyloid and anti-inflammatory natural polyphenol curcumin (the principal ingredient from the root extract of Curcuma longa) has been used in several neurodegenerative diseases, including AD. It can reduce amyloid burden, rescue neuronal damage and restore normal cognitive and sensory motor functions in different animal models of AD. Interestingly, it is not only neuroprotective, but also has preferential binding to misfolded A. Therefore, Cur has been considered a promising natural compound to use as therapeutics as well as detection of A plaques in AD. This mini-review highlighted the therapeutic targets, including possible molecular pathways of curcumin action to rescue neurodegeneration in AD. This article should help to researcher for basic understanding of the molecular mechanism of action of curcumin to use as therapeutics to fight against neurodegeneration in AD.
No takes yet. Share an insight, caveat, or question.
A 2016 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: